The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Targeting the BRAF V600E Mutation in Multiple Myeloma
Abstract
In multiple myeloma, there has been little progress in the specific therapeutic targeting of oncogenic mutations. Whole-genome sequencing data have recently revealed that a subset of patients carry an activating mutation (V600E) in the BRAF kinase. To uncover the clinical relevance of this mutation in multiple myeloma, we correlated the mutation status in primary tumor samples from 379 patients with myeloma with disease outcome. We found a significantly higher incidence of extramedullary disease and a shorter overall survival in mutation carriers when compared with controls. Most importantly, we report on a patient with confirmed BRAF V600E mutation and relapsed myeloma with extensive extramedullary disease, refractory to all approved therapeutic options, who has rapidly and durably responded to low doses of the mutation-specific BRAF inhibitor vermurafenib. Collectively, we provide evidence for the development of the BRAF V600E mutation in the context of clonal evolution and describe the prognostic and therapeutic relevance of this targetable mutation. Significance: This is the first evidence of the clinical and therapeutic relevance of BRAF V600E mutations in multiple myeloma, proving the principle of specific inhibition of driver mutations in this disease. Cancer Discov; 3(8); 862–9. ©2013 AACR. See related commentary by O'Donnell and Raje, p. 840 This article is highlighted in the In This Issue feature, p. 826
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
The genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Cited by
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988
Genomic complexity of multiple myeloma and its clinical implications
Manier, S., Salem, K. Z., Park, J., Landau, D. A., Getz, G., & Ghobrial, I. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.122 · Cited by 560
Kortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C.-X., Zhu, Y.-X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698092 · Cited by 255
Self-citationEmerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks
Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020) · Genes · doi:10.3390/genes11111342 · Cited by 168
In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data
Celebi, R., Bear Don’t Walk, O., Movva, R., Alpsoy, S., & Dumontier, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-45236-6 · Cited by 120
Metadata
- Authors
- Andrulis, M., Lehners, N., Capper, D., Penzel, R., Heining, C., Huellein, J., Zenz, T., von Deimling, A., Schirmacher, P., Ho, A. D., Goldschmidt, H., Neben, K., & Raab, M. S.
- Venue
- Cancer Discovery
- Published
- 2013-08-01
- Volume
- 3
- Issue
- 8
- Pages
- 862-869
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2158833600
- Cited by
- 234
- References
- 7
- FWCI
- 18.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the BRAF V600E Mutation in Multiple Myeloma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0014
- The paper
- Andrulis, M., Lehners, N., Capper, D., Penzel, R., Heining, C., Huellein, J., Zenz, T., von Deimling, A., Schirmacher, P., Ho, A. D., Goldschmidt, H., Neben, K., & Raab, M. S. (2013). Targeting the BRAF V600E Mutation in Multiple Myeloma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.